inhibitor have been calculated over 3-years and compared for the two scenario analyses. Emicizumab price was assumed equal to 210.2V/mg in order to have the same annual costs of aPCC prophylaxis. Sensitivity analyses were performed to identify the price scenario where emicizumab reported a neutral budget impact. RESULTS: Based on actual treatment utilization data in Italy, the model estimated a 3-years overall cost of 368,839V mln in all hemophilic patients with inhibitor (mean cost per patient/ year ¼723,213V). Assuming a possible switch also from less expensive regimens (on-demand and high dose rFVIII prophylaxis) to emicizumab prophylaxis, a budget impact of +38.5Vmln (+10%) was reported over three-years. Changing emicizumb price, a neutral budget impact was obtained at 157.6V/mg (-25% of basecase price). CONCLUSIONS: The budget estimation is sensitive to emicizumab price. A neutral budget impact can be obtained if emicizumab price was set to 157.6V/mg. Below the neutral price, emicizumab prophylaxis use could save millions of euro. For example, an expected budgetary saving of 39.0V mln was estimated assuming a price of 105.10V/mg.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.